Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808103 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
A Phase 1 study of Crohn Disease, sponsored by Intralytix.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT03808103: Active Phase 1 study of Crohn Disease, sponsored by Intralytix.
NCT03808103 is a Phase 1 study of Crohn Disease that is active but no longer recruiting, run by Intralytix. The registered enrollment target is 30 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03808103, a Phase 1 study of Crohn Disease, is active but no longer recruiting, sponsored by Intralytix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
Primary Outcome
The number of solicited and unsolicited adverse events will be recorded.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Bacteriophage preparation
Study Locations (2)
Maryland
- Johns Hopkins Green Spring Station - Lutherville
New York
- Icahn School of Medicine at Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 1 |
What the registry record for NCT03808103 still lists
NCT03808103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03808103 reports a single indexed study location in Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT03808103 about?
NCT03808103 is a clinical study titled "Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease". This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
What is the current status of trial NCT03808103?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-05-01. Estimated completion is 2026-06-01.
What conditions does trial NCT03808103 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT03808103?
The interventions under investigation include: Placebo (BIOLOGICAL), Bacteriophage preparation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03808103?
This trial is sponsored by Intralytix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03808103 being conducted?
This trial has 2 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03808103's enrollment target sits among peer trials
30 52nd of 71 higher than 16 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
-
Stem Cell Transplantation in Crohn's Disease
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
COMPLETED · Phase 1
-
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI